Kornimate/medical-research-clean huggingface dataset:
the innate immune system and inflammatory bowel disease

Conditions: Ulcerative Colitis; Crohn's Disease

Summary: the study includes individuals with ulcerative colitis, crohn's disease and healthy controls. the purpose of this study is to examine the innate immune system (iis) by exposing peripheral blood monocytes to various ligands relevant for stimulation of the iis and study the immune response. colonic mucosal samples are examined to find gene expression patterns which may distinguish the two forms of disease from each other and from healthy controls. the hypothesis is that the innate immune system has responses unique for the disease states, and that the diseases may be differentiated by examination of gene expression patterns in mucosal biopsies.


Eligibility criteria:
inclusion criteria: * presence of ulcerative colitis * presence of crohn's disease * healthy (no sign of inflammatory bowel disease) exclusion criteria: * anticoagulation * cardiac valvular disease * intravascular prosthesis * coagulation disorders * gastrointestinal malignancy
validation of the utility of strabismus intelligent diagnostic system

Conditions: Ophthalmological Disorder; Strabismus

Summary: strabismus affects approximately 0.8%-6.8% of the world's population and appears by the age of 3 years in 65% of affected individuals. manual measurement of deviation is often laborious and highly dependent on the experience of the specialist and the cooperation of the patients. current strabismus evaluation technologies are heavily dependent on model eyes. here, the investigators use deep learning to develop an artificial intelligence (ai) platform consisting of three deep learning (dl) systems to screen strabismus, evaluate deviation and propose a surgical plan based on corneal light-reflection photos. the investigator also conduct clinical trial to validate its versatility in clinical practice.


Eligibility criteria:
inclusion criteria: * patients in the outpatient clinic of strabismus department. exclusion criteria: * patients or their parents diagree to participate in the trial. * patients with blepharoptosis. * patients can't facing forward or lacking fixation.
caregivers preparing for their own health care emergency

Conditions: Dementia; Caregiver Burden

Summary: the proposed research will develop and test an online emergency preparedness toolkit to help caregivers prepare for their own unexpected health events. caregivers of persons with dementia often ignore their own health needs as their primary focus is the care of the person with dementia. this can lead to a caregiver delaying their own care and subsequently emergent health events. the emergency preparedness toolkit provides guidance to the caregiver as to how to identify and transfer care to a standby caregiver. the goal is to provide a caregiver with the security and comfort that the person with dementia will be well cared for while they care for their own health needs.


Eligibility criteria:
inclusion criteria: * must be 18 years of age or older at the time of signing the informed consent * must self-identify as the spouse or partner of the pwd * must provide some caregiving to a pwd * must live in the same dwelling as the pwd exclusion criteria: * diagnosis of dementia * unable to use or does not have access to a computer * complete deafness or blindness and/or unable to use a telephone * condition that prevents them from performing caregiving duties or providing physical/emotional support to the pwd * unable to follow directions * unable to read or write in english * participation in prior study involving the ept
analysis of circulating exosomes in melanoma patients

Conditions: Melanoma

Summary: the hypothesis is that pd-l1\[programmed death-ligand 1\] labeling in exosomes could be a biomarker of disease progression in melanoma. the rate of circulating exosomes, their size and the exosomal expression of pd-l1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients. in this study, blood samples (edta tubes taken as part of routine care at besançon university hospital) and associated clinical data are reused.


Eligibility criteria:
inclusion criteria: * melanoma patients admitted in besançon university hospital * exigible for immunotherapy such as anti pd-l1/pd-1 * age ≥18 years * affiliation to a social security system, exclusion criteria: * minor patients * patients who have expressed their opposition to the reuse of their data and biological samples
a prospective observational study to evaluate acute kidney injury biomarkers in patients receiving first cycle of cisplatin chemotherapy for head and neck cancers

Conditions: Head and Neck Cancer

Summary: the project is designed to test new biomarkers that are more sensitive than the current standard in detecting injury to the proximal kidney tubule and will establish better criteria for when kidney safety concerns may halt further testing of a drug in humans.

the study will be conducted at four major medical centers, including the university of southern california, the university of minnesota, the dana farber cancer institute, and the md anderson cancer center. blood and urine samples will be collected from patients undergoing treatment with either cisplatin or aminoglycosides, which are two different drugs known to cause injuries to the proximal tubule of the kidney. cisplatin is a common chemotherapy drug taken by patients with head and neck cancer. aminoglycosides are a common antibiotic drug taken by patients with cystic fibrosis.

Eligibility criteria:
inclusion criteria (cisplatin treatment group): 1. males and females ≥ 18 years of age 2. diagnosis of head \& neck cancer and confirmation that patient is due to receive a 1st cycle of cisplatin (75-100 mg/m2/cycle) chemotherapy either: * as single agent chemotherapy in conjunction with local radiotherapy course, or * as part of the tpf combination (docetaxel, cisplatin, and fluorouracil) 3. willingness and ability to comply with study procedures and study restrictions 4. ability to provide written informed consent inclusion criteria (control group): 1. males and females ≥ 18 years of age 2. diagnosis of head \& neck cancer or similar condition such as an upper body, localised malignancy. these control patients will be scheduled to receive a non-nephrotoxic treatment modality (e.g. local radiotherapy alone) 3. willingness and ability to comply with study procedures and study restrictions 4. ability to provide written informed consent exclusion criteria (all subjects): 1. chronic kidney disease defined by egfr \ 30 mcg/mg creatinine) will be excluded 2. patients currently receiving other potentially nephrotoxic agents (i.e. chronic use of high dose nsaids, intravenous aminoglycosides, intravenous colistin, intravenous vancomycin, or acei) 3. any major surgery (i.e. high risk of acute kidney injury) in the previous month 4. patients currently receiving trimethoprim or cimetidine or other medications known to alter the tubular secretion of creatinine 5. use of creatine supplements within 7 days prior to hospitalization 6. solid organ transplant recipients 7. abnormal liver function (serum alt, ast or total bilirubin \>2xuln) 8. significant anemia (hemoglobin \< 10 g/dl) 9. pregnancy 10. institutionalized individuals

Keywords: kidney safety biomarkers serum creatinine bun cystic fibrosis head and neck cancer renal injury drug induced acute kidney injury aminoglycoside cisplatin nephrotoxicity biomarker qualification
study of taxoprexin injection vs. dacarbazine in patients with metastatic malignant melanoma

Conditions: Malignant Melanoma

Summary: the primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with taxoprexin injection to those treated with dacarbazine. in addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be measured. toxicity will be evaluated and compared between the two groups.


Eligibility criteria:
inclusion criteria: * patients must have malignant melanoma, and documented metastatic disease. * patients must have at least one unidimensionally measurable lesion. * patients must not have received prior systemic chemotherapy for metastatic disease. prior treatment with immunotherapy or vaccine therapy is allowed provided there is documentation of disease progression. * at least 6 weeks (42 days) since any prior immunotherapy, cytokine, biologic, vaccine or other therapy unless patients have progressed during immunotherapy. * at least 4 weeks (28 days) since any prior radiotherapy. * lesions being used to assess disease status may not have been radiated. * patients must have ecog performance status of 0 - 2. * patients must be \>= 18 years of age. * patients must have adequate renal and liver function * patients must have adequate bone marrow function. * life expectancy of at least 3 months. * patients must sign an informed consent form indicating that they are aware of the investigational nature of this study and in keeping with the policies of the institution. exclusion criteria: * patients who have received prior therapy with any taxane or dacarbazine. * patients whose primary site is the eye. * patients who have a past or current history of neoplasm other than the entry diagnosis, except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix or other cancers cured by surgery alone with a disease-free survival longer than 5 years. * patients with uncontrolled brain metastasis. * patients who are pregnant or nursing and patients who are not practicing an acceptable method of birth control. patients may not breastfeed while on this study. * patients with current active infections requiring anti-infectious treatment (e.g., antibiotics, antivirals, or antifungals). * patients with current peripheral neuropathy of any etiology that is greater than grade 1. * patients with unstable or serious concurrent medical conditions are excluded. * patients with a known hypersensitivity to cremophor. * patients must not have had recent major surgery within the past 14 days or large field radiation therapy, chemotherapy, endocrine therapy in the last 28 days, or biologic therapy in the last 42 days.
ambulatory telemonitoring of people with hearing loss and having a cochlear implant cochlesurv

Conditions: Deafness

Summary: the number of patients with cochlear implants increases every year, constituting an active queue increasingly important (60 new cases per year in toulouse, active list in 2013: 380 adult patients). the number of approved cochlear implant centers is limited by guardianships, and corresponds to the hospitals university. it is not possible to create networks of correspondents. teams of implantation centers must meet the needs of new patients and ensure continuity of care for patients already implanted: speech therapy monitoring, adjustment and rehabilitation. in case of malfunction of the implant, patients use in first-line reference center. the increasing number of patients leads to a lack of specialized teams that can not meet the demands of patients in a timely manner, while continuing to provide support for new patients. it is therefore necessary to find solutions to improve the service provided to patients who received a cochlear implant system to respond quickly and effectively to the request of troubled patients, while optimizing the workload of the teams . the introduction of a telemedicine platform is expected to achieve these goals, distinguishing minor malfunctions, not requiring a consultation in a center, and the most complex situations requiring consultation in a center.

the strategy of the study is to establish contact with the patient at home in case of problems through the establishment of a daily continuously in service by telephone contact and video calling. there will be no change in the usual care of the patient. the monitoring center by health professionals (speech therapists, technicians and doctors orl) in the cochlear implant center will operate a daily permanence of 5 half days on business days, to respond to a patient call. are excluded from this research, emergency management such as meningitis, which passes through the usual emergency lane.

Eligibility criteria:
inclusion criteria: * adult patient (\> 18 years), carrying a cochlear implant, * familiar with using the internet and with equipment (computer and computer video camera) at his home * agreeing to participate in the study, * with a social protection system. exclusion criteria: * misunderstanding of login procedures, * failure to follow procedures, * person under a legal protection system (guardianship, curators or safeguard justice) * pregnancy or breastfeeding.

Keywords: cochlear implant telemedicine new organization of patient monitoring
effect of leg strengthening exercise after hip fracture

Conditions: Hip Fractures

Summary: the purpose of this trial was to examine the effectiveness of a short-term leg strengthening exercise program compared to attention control on improving leg strength, walking speed and endurance, physical performance, and physical function one year after hip fracture.

poor functional outcomes are reported for the majority of older adults who sustain a hip fracture. the ability of hip fracture patients to make sustained functional improvements above and beyond natural recovery is unknown. it has been shown that gym-based programs can help old adults regain function after hip fracture. it is unclear if these results could be translated into the home setting that lacks the gym-based equipment, or if improvement would be sustainable. this program compares high intensity strength training performed in the home twice weekly for 10 weeks to an attention placebo control in which participants receive sensory electrical stimulation to leg muscles.

Eligibility criteria:
inclusion criteria: * successful fixation (partial or total hip replacement or open reduction internal fixation) of a hip fracture within the last 6 months * were 65 years of age or older, were living at home prior to the fracture, had a physician referral and were discharged from physical therapy. exclusion criteria: * medical history of unstable angina or uncompensated congestive heart failure, ongoing chemotherapy or renal dialysis, history of stroke with residual hemiplegia, parkinson disease, absent sensation in the lower extremities due to sensory neuropathy, life expectancy of less than 6 months, and folstein mental status scores \< 20.

Keywords: hip fracture exercise rehabilitation functional performance
efficacy and safety of polymer-free amphilimus-eluting stent according to the diabetes

Conditions: Diabetes Mellitus; Coronary Artery Disease

Summary: drug-eluting stents (des) have been found to reduce the rate of stent restenosis compared to bare metal stents (bms), but the first generation des caused an increase in stent thrombosis. the second generation des, including the cre8evo stent, has been designed to address these issues. the cre8evo stent is made of cobalt chromium and releases the drug amphilimus into the vessel wall, which is quickly absorbed and then lost, creating a bms-like form. the cre8evo stent does not contain polymers and does not induce an inflammatory response. it inhibits cdk2 and rhoa, reducing the proliferation and migration of vascular smooth muscle cells. in diabetic patients, the cre8evo stent showed superior results in suppressing late proliferation compared to conventional des. the cre8evo stent has been found to be safe and effective in clinical studies, and it has a superior effect in the clinical course of diabetic patients compared to other stents. the purpose of the study is to evaluate the effectiveness and safety of the cre8evo stent in actual clinical practice, specifically comparing outcomes in patients with and without diabetes.


Eligibility criteria:
inclusion criteria: * age 19 or older * patients who agreed to the research protocol and clinical follow-up plan, voluntarily decided to participate in this study, and gave written consent to the consent form ③ patients who underwent coronary angioplasty by inserting cre8™ or cre8™ evo stent for coronary artery disease for a lesion confirmed within the last 1 month exclusion criteria: * patients with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, amphilimus, cobalt chrome, stainless steel nickel, 316l metal, and contrast media if it can be controlled by pheniramine and pheniramine, registration is possible, but if there is known anaphylaxis, it is excluded.) * pregnant women, lactating women, or women of childbearing age who are planning to become pregnant during the study period ③ patients who are planning surgery to stop antiplatelet drugs within 12 months from registration * patients whose remaining life expectancy is expected to be less than 1 year * patients who visited the hospital due to cardiogenic shock and are predicted to have a low survival rate based on medical judgment ⑥ subjects participating in medical device randomization research ⑦ patients who underwent surgery using a stent other than cre8™/cre8™ evo at the time of registration
phase 2 safety and efficacy study of a vitamin d compound (dp001) in postmenopausal women with low bone mineral density

Conditions: Osteoporosis

Summary: this study will evaluate the effect of a 1-year administration of the vitamin d analog 2-methylene-19-nor-(20s)-1alpha, 25-dihydroxyvitamin d3 (dp001) on bone mineral density (bmd), safety, and tolerability.

dp001 is a vitamin d analog that has been shown to stimulate bone formation in pre-clinical studies. in a phase 1b study of postmenopausal women, an increase in the bone formation marker, osteocalcin, was evident without an increase in serum calcium. the aim of this study is to determine if 1-year administration of dp001 to postmenopausal women with osteopenia results in a significant increase in bmd at doses that are safe and well tolerated.

Eligibility criteria:
inclusion criteria: * postmenopausal female subjects, defined as amenorrheic for at least 5 years * body mass index of 18 to 35 * osteopenic * generally healthy * informed consent exclusion criteria * history or evidence of acute or unstable chronic hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases * current or recent treatment with any medications or products affecting vitamin d metabolism, calcium balance, bone turnover, or an investigational drug therapy * 12-lead electrocardiogram demonstrating qtc (qt interval corrected for heart rate) \>450 milliseconds at screening * abnormal creatinine clearance * elevated urinary calcium levels * vitamin d deficiency * excessive dietary calcium or vitamin d intake * current use of any illicit drug and/or history of alcohol abuse

Keywords: osteoporosis 2-methylene-19-nor-(20s)-1a, 25-dihydroxyvitamin d3 vitamin d bone density conservation agents bone regeneration
herpes simplex reactivation in adult critical care patients

Conditions: Herpes Simplex I; Herpes Simplex II

Summary: welcome or not herpes simplex virus (hsv) is an ever present guest in the intensive care unit (icu). several studies have documented a high frequency of hsv reactivation in critically ill patients despite that clinical impact remains unknown.

normally primary hsv infection is asymptomatic but can under certain circumstances cause manifestations such as encephalitis and bronchopneumonitis. bruynseels showed that hsv was detectable in the throat of two percent of healthy volunteers and three percent of patients not admitted to the icu, this provides a broad "recruitment-base" for either latent or lytic hsv infection in the icu. viral dissemination to the bloodstream is seen in neonates , immunocompromised patients, but also in patients with primary herpetic gingivostomatitis. patients testing polymerase chain reaction (pcr) positive for herpes simplex dna in blood, have a higher rate of systemic symptoms than those testing pcr negative for herpes simplex. additionally it is known that hsv suppression in hiv patients has beneficial effects. pcr, now being available for more than a decade, has been shown to provide a more sensitive method for the detection of hsv than culture, but viral detection does not per se translate to viral disease thus the impact of disseminated hsv infection in icu patients remains unclear. the investigators would like to investigate the incidence of hsv reactivation in blood and tracheal secretions critically ill patients and its impact on clinical course.

Eligibility criteria:
inclusion criteria: * admission to icu * expected length of stay (los) \>72 hours * intubated \<24 hours prior to inclusion * informed consent by patient, relative or guardian exclusion criteria: * ongoing antiviral treatment/prophylaxis * expected los \<72 hours * intubation \>24 hours prior to inclusion * withdrawal of informed consent
antibacterial effect of zinc oxide nanoparticles on acinetobacter baumannii isolated from patients with hospital acquired infections in sohag university hospitals, egypt

Conditions: Infections, Nosocomial; Infections, Respiratory Tract

Summary: a. baumannii is known as the most frequently isolated organism in intensive care units (icus), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (utis), bacteremia as well as skin and soft tissue infections. these infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among icu patients.

acinetobacter baumannii (a. baumannii) is gram- negative, aerobic, glucose non-fermentative, non-motile coccobacillus, ubiquitous in nature, and persistent in healthcare settings. it is regarded as a significant opportunistic human pathogen. this bacterium become a growing problem in hospitals as a predominant multidrug-resistant (mdr) bacterium. horizontal acquisition of resistance genes is the main factor involved in the emergence of mdr . there are many mechanisms to confer resistance to different classes of antibiotics in a. baumannii, one of them is multidrug efflux pumps. these efflux pumps are important source of mdr, which export antibiotics from the cell, increasing their antibiotic resistance. adeabc is one of the most important efflux systems, belonging to the rnd family in acinetobacter, which plays an important role in the resistance to a broad group of antibiotics; its genes are chromosomal and encode three genes, i.e., adeb, adea, and adec, forming an operon in the vicinity. in addition, the expression of adeabc is done by a two-component system, which includes a response regulator (ader) and a sensor kinase (ades) . the ability of acinetobacter spp. to form biofilm that enables bacterial survival in hospital settings, especially in icus, is the most significant contributing factor to their virulence, and this trait is also responsible for their notable antibiotic resistance. several biofilm-related genes influence antimicrobial susceptibility, suggesting an association between the biofilm-forming ability of acinetobacter spp. and their antibiotic resistance patterns (mdr/xdr) zinc oxide nanoparticles (zno nps) are one of the most important nanoparticles of metal oxides; it is a unique and inorganic materials that can be used in several biological applications (anti-bacterial, anti-inflammatory). zno nps exhibit distinctive properties other than other nanoparticles such as higher solubility, better biofilm penetration and effective drug delivery . zno nps have been reported to have antimicrobial properties such as disrupting the cell membrane of pathogens, accumulating in the cell and producing toxic h2o2 (hydrogen peroxide)

Eligibility criteria:
inclusion criteria: * all patients suffering from infections that can be caused by a. baumannii. exclusion criteria: * all patients suffering from infections that aren\&#39;t caused by a. baumannii.

Keywords: a. baumannii. biofilm zno nps hospital aquired infections